OBT646

OBT646 is an investigational antibody-drug conjugate (ADC) currently in the discovery stage of development by Oxford BioTherapeutics. The therapeutic is designed to target a specific, undisclosed cell-surface antigen on tumor cells to deliver a cytotoxic payload, a strategy intended to maximize anti-tumor activity while minimizing systemic toxicity. The target for OBT646 was identified using the company's proprietary Oxford Genome Anatomy Project (OGAP®) database, which integrates genomic and proteomic data to discover novel membrane proteins overexpressed in solid tumors. As part of Oxford BioTherapeutics' oncology pipeline, OBT646 represents a targeted approach to treating cancer by utilizing the specificity of monoclonal antibodies to deliver potent cell-killing agents directly to the tumor microenvironment.